2022; 6.. O-01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB-SAHARAN AFRICA: THE REACH EXPERIENCE. HemaSphere.
Neonatal vascular anomalies manifesting as soft-tissue masses. Pediatric Radiology. 2022; 52:786-801..
2022; 140:5416-5417.. Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial. Blood.
Pediatric Hydrocephalus in Northwest Tanzania: A Descriptive Cross-Sectional Study of Clinical Characteristics and Early Surgical Outcomes from the Bugando Medical Centre. World Neurosurgery. 2022; 161:e339-e346..
MPN-024 Hypereosinophilic Syndrome: A Catastrophic Pediatric Case. Clinical Lymphoma, Myeloma and Leukemia. 2022; 22 Suppl 2..
2022; 22.. Poster: MPN-024 Hypereosinophilic Syndrome: A Catastrophic Pediatric Case. Clinical Lymphoma, Myeloma and Leukemia.
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain. Haemophilia. 2022; 28:453-461..
Forward: Welcome to the Special Issue on Vascular Anomalies. Pediatric Blood and Cancer. 2022; 69 Suppl 3..
Urinary 11-dehydrothromboxane B2 aspirin efficacy testing is sensitive to perioperative inflammation in pediatric solid-organ transplant patients. Pediatric Blood and Cancer. 2022; 69..
Hemostasis and tumor immunity. Research and Practice in Thrombosis and Haemostasis. 2022; 6..
2022; 208:121.12-121.12.. The role of the Thrombin/PAR axis in modulating CD8+ T cell anti-tumor immunity. Journal of Immunology.
2022; 140:63-64.. U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics. Blood.
2022; 140:5593-5594.. Obesity and Race As Determinates of Plasma Von Willebrand and Factor VIII Levels. Blood.
2022; 140:5418-5419.. Return Visit Rates after an Emergency Department Treat-and-Release Visit for Children with Sickle Cell Pain Episodes. Blood.
2022; 140:8168-8169.. Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT). Blood.
2022; 140:8256-8257.. Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis. Blood.
2022; 142.. LB1033 Thrombin contributes to atopic dermatitis pathogenesis and staphylococcus aureus skin colonization in children. Journal of Investigative Dermatology.
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. Clinical Pharmacology in Drug Development. 2022; 11:654-665..
Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis. American Journal of Hematology. 2022; 97:1384-1385..
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA - Journal of the American Medical Association. 2022; 327:129-137..
The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology. Blood Advances. 2022; 6:6187-6197..
Thrombin mediated activation of PAR1 enhances doxorubicin induced cardiac injury in mice. Blood Advances. 2022..
2022; 140:10857-10859.. Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia. Blood.
The influence of perceived racial bias and health-related stigma on quality of life among children with sickle cell disease. Ethnicity and Health. 2022; 27:833-846..
Suppression of fibrin(ogen)-driven pathologies in disease models through controlled knockdown by lipid nanoparticle delivery of siRNA. Blood. 2022; 139:1302-1311..
2022; 81.. Total pancreatectomy with islet autotransplantation in a child with pancreatic kaposiform hemangioendothelioma. Journal of Pediatric Surgery Case Reports.
Early hydroxyurea use is neuroprotective in children with sickle cell anemia. American Journal of Hematology. 2022; 97:E368-E370..
A Murine Model of Veno-Arterial Extracorporeal Membrane Oxygenation. ASAIO Journal. 2022; 68:e243-e250..
Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022; 140:1156-1166..
2022; 6:07-08.. O-12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW-RESOURCE SETTINGS. HemaSphere.
Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies. Blood Advances. 2022; 6:4645-4656..
2022; 6:02-03.. O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH. HemaSphere.
2022; 7.. Case Report: β-thalassemia major on the East African coast. Wellcome Open Research.
Blood diseases in Africa: Redressing unjust disparities is an urgent unmet need. American Journal of Hematology. 2022; 97:1505-1506..
Results of an international survey on adherence with anticoagulation in children, adolescents, and young adults: Communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis. 2022; 20:1720-1728..
2022; 12:11-28.. Health Related Quality of Life among Children with Sickle Cell Anaemia in Northwestern Tanzania.
Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. mBio. 2022; 13..
2022.. Chapter 3 Classification and diagnosis of anemia in children and neonates. Lanzkowsky's Manual of Pediatric Hematology and Oncology.
M-CSF supports medullary erythropoiesis and erythroid iron demand following burn injury through its activity on homeostatic iron recycling. Scientific Reports. 2022; 12..
Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening. FASEB Journal. 2022; 36..
The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Blood Advances. 2022; 6:679-685..
Crosstalk between hemostasis and immunity in cancer pathogenesis. Thrombosis Research. 2022; 213 Suppl 1:S3-S7..
Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Advances. 2022; 6:5821-5828..
US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Pediatric Blood and Cancer. 2022; 69..
Reproductive equity: preserve the reserve. Blood. 2022; 139:963-965..
New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?. Pediatric Blood and Cancer. 2022; 69..
2022; 6.. PI-08: HIGH DISEASE BURDEN, MORBIDITY AND MORTALITY AMONG CHILDREN WITH SICKLE CELL ANAEMIA IN UGANDA. HemaSphere.
An Immersive Virtual Reality Curriculum for Pediatric Hematology Clinicians on Shared Decision-making for Hydroxyurea in Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology. 2022; 44:e799-e803..
How we approach the diagnosis and management of complex lymphatic anomalies. Pediatric Blood and Cancer. 2022; 69 Suppl 3..
Erythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis. Blood. 2022; 140:1621-1634..
Diagnostic Considerations in H1N1 Influenza-induced Thrombotic Microangiopathy. Journal of Pediatric Hematology/Oncology. 2022; 44:e237-e240..
Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. Blood Advances. 2022; 6:420-428..
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. Journal of Pharmacology and Experimental Therapeutics. 2022; 380:210-219..
How we approach genetics in the diagnosis and management of vascular anomalies. Pediatric Blood and Cancer. 2022; 69 Suppl 3..
2022; 140:8190-8191.. Dominant-Negative VPS4A Mutations Causing Congenital Dyserythropoietic Anemia Disrupt Iron Trafficking of Terminal Erythropoiesis. Blood.
2022; 140:13141-13142.. A Health Equity Echo for Providers of Children and Adults with Sickle Cell Disease. Blood.
Expanding a Regional Sickle Cell Disease Project ECHO® to Rapidly Disseminate COVID-19 Education. Advances in Medical Education and Practice. 2022; 13:443-447..
2022; 6:43-44.. P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere.
A systematic review of adherence to anticoagulation regimens in pediatric patients. Pediatric Blood and Cancer. 2022; 69..
Altered erythropoiesis in newborns with congenital heart disease. Pediatric Research. 2022; 91:606-611..
Autism-associated chromatin remodeler CHD8 regulates erythroblast cytokinesis and fine-tunes the balance of Rho GTPase signaling. Cell Reports. 2022; 40..
Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation. Blood Advances. 2022..
2022; 140:1234-1235.. De Novo Germline DHX38 Variant Associated with Alternative Splicing of Multiple Transcripts in Iron-Related Pathways in a Patient with Atypical Congenital Dyserythropoietic Anemia with Ring Sideroblasts. Blood.
Use of thromboelastography in children on extracorporeal membrane oxygenation. Journal of Pediatric Surgery. 2022; 57:1056-1061..